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THE stimulation  of  granulocyte  macrophage-colony
stimulating  factor  (GM-CSF)  by  interleukin-1  (IL-1)
has  been  shown  to  be  counteracted  in  different
mesenchymal  cell  systems  by  cyclic  adenosine
monophosphate  (cAMP)  agonists.  The  aim  of  this
study was the evaluation of different cAMP agonists
on  GM-CSF  expression  in  human  bone  marrow
stromal  cells.  Incubation  of  secondary  haemato-
poietic progenitor cell deprived human stromal cell
cultures with IL-1 or TNF-a induced GM-CSF protein
expression  in  culture  supernatants  and  GM-CSF-
mRNA  in  adherent  stromal  cells.  The  coincubation
with 8-bromo-cAMP (8BrcAMP), a water soluble cAMP
analogue,  inhibited  this  GM-CSF  stimulation  at  the
protein  and  the  mRNA  level.  This  effect  was  dose
dependent with a maximal inhibition of about 65%
occurring at a 8BrcAMP concentration of 0.75 mM. In
addition  to  8BrcAMP,  other  cAMP  agonists  such  as
dibutyryl-cAMP, forskolin, pertussis toxin, or prosta-
glandin E2 (PGE2) had the same inhibitory effect on
GM-CSF  stimulation  by  IL-1.  Coincubation  with  the
cyclooxygenase inhibitor indomethacin had  no sig-
nificant influence on GM-CSF expression in stromal
cells. Our results provide evidence that the previously
described inhibitory effect of cAMP agonist PGE2 on
haematopoietic progenitor cells in vivo is, at least in
part, mediated by modulating the expression of GM-
CSF in bone marrow stromal cells.
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Introduction
The bone marrow stroma provides a microenviron-
ment for proliferation and differentiation of haemato-
poietic stem and progenitor cells. Stromal cell cyto-
kine production plays a pivotal role in controlling the
development of sufficient mature blood cells under
normal demands or after stimulation by inflammatory
processes.1 GM-CSF is a potent growth factor  for a
variety  of  haematopoietic  progenitor  cells.  It  is
produced  by  T -lymphocytes,  macrophages  and  a
variety of mesenchymal cells.2
Long-term  bone  marrow  Dexter  type  cultures
support  the  prolonged  proliferation  of  haemato-
poietic progenitor cells, thereby providing an in vitro
model  for  studies  aimed  at  elucidating  the  mecha-
nisms  involved  in  haematopoietic  regulation.  The
adherent  layer  of  Dexter  cultures  is  composed  of
mesenchymal bone marrow stromal cells.3The regula-
tion of growth factor production in the adherent layer
of  Dexter  type  long-term  bone  marrow  cultures
closely  resembles  the  in  vivo situation.  Multiple
cytokines  have  been  found  in  the  supernatant  of
Dexter  cultures,  including  GM-CSF ,  G-CSF ,  M-CSF ,
interleukin-6, and leukaemia  inhibitory factor (LIF).
GM-CSF expression in mesenchymal cells is induced
by inflammatory cytokines like IL-1 or TNF-a and is
controlled  at  both  the  transcriptional  and  post-
transcriptional levels.4–6
In this study, we used human stromal cell cultures
to evaluate the effects of cAMP on the expression of
GM-CSF ,  induced  by  inflammatory  cytokines.  We
demonstrated that a variety of cAMP agonists inhibit
the production of GM-CSF at the protein and mRNA
level. These data indicate that the inhibitory effect of
cAMP agonists like PGE2 on haematopoietic progeni-
tor cells are, at least in part, mediated by modulating
the expression of growth factors like GM-CSF in the
bone marrow microenvironment.
Materials and Methods
Material
rh-IL-1a was kindly provided by Hoffmann La Roche
(Nutley, NJ), and rh-TNFa (6.6 3 106 U/mg) by Knoll
AG (Ludwigshafen, Germany). Indomethacin, pertus-
sis  toxin,  dibutyryl-cAMP ,  8BrcAMP ,  PGE2,  and  for-
skolin were purchased from Sigma  Chemicals  (Dei-
senhofen,  Germany),  and  a -32P-labelled  nucleotides
from Amersham Buchler (Braunschweig, Germany).
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Adherent  bone  marrow  stromal  cell  cultures  were
essentially  obtained  as  previously described.7 Bone
marrow mononuclear cells, separated by centrifuga-
tion  over  Ficoll-Hypaque,  were  incubated  at  a  cell
density of 1 3 106/ml in 25cm2 tissue flasks at 33°C in
culture  medium  consisting  of  RPMI  1640  supple-
mented with 10% fetal calf serum (FCS), 10% horse
serum, 1.0m M hydrocortisone (Sigma Chemicals), and
the  additives  as  described.7 In  weekly  intervals,
cultures  were  fed  by replacing  75%   of  the  culture
medium. When cultures were covered more than 80%
by adherent cells, the primary cultures were treated
with  trypsin-EDTA  (Biochrom,  Berlin,  Germany).
Detached stromal cells were pooled and expanded in
new culture flasks at a surface ratio of 1:5 in 75cm2
tissue flasks. The adherent cells were incubated under
the same culture conditions until the cultures became
confluent  again.  By  this  culture  method,  homoge-
neous  stromal  cell  layers  were  obtained that  were
morphologically and functionally comparable in differ-
ent culture flasks. These cultures were devoid of all
haematopoietic cells, including macrophages. Hydro-
cortisone was removed from these cultures at least 3
days before use for RNA and protein analysis. GM-CSF
was measured in the culture supernatants of stromal
cells after incubation for 24h with various factors, as
indicated in the Results section. For RNA analysis, the
factors, as indicated in the Results section, were added
simultaneously to parallel culture flasks from the same
donor. After 6h the cells were lysed directly in the
culture  flask  with  guanidium-isothiocyanate  lysis
buffer and processed as described below. The content
of a 75cm2 tissue flask yielded 10–20m g total RNA.
Northern blot analysis
Total cytoplasmic RNA was prepared using the single
step method of guadinium/phenol-chloroform extrac-
tion  as  described  earlier.8 Ten  to  15m g  of  RNA
(depending  on  the  least  yield  obtained  in  each
experiment) were subjected to electrophoresis on a
1%  agarose-formaldehyde  gel  and  transferred  onto
nylon  membrane  (Hybond-N,  Amersham  Buchler).
Blots were hybridized to a 32P-labelled cDNA probes
using random primer DNA labelling kit (Boehringer),
washed  and  exposed  to  Cronex-4  autoradiography
films (DuPont) at –70°C. Human GM-CSF cDNA, an
800-bp EcoRI fragment cloned into P91023(B)-vector,
was obtained from American Type Culture Collection
(Rockville, MD).
Enzyme-linked immunoabsorbent assay
(ELISA)
Concentrations  of  GM-CSF  were  measured  using
Quantikine Human Cytokine Immunoassays (R&D Sys-
tems, Minneapolis, MN) according to manufacturer’s
instructions. Sensitivity of the test for human GM-CSF
was 7.8pg/ml.
Results
Stimulated GM-CSF expression in human bone
marrow stromal cells is inhibited by 8BrcAMP
Expression  of  GM-CSF  in  human  bone  marrow
stromal  cells  was  assessed  at  the  protein  level  in
culture supernatants by a sensitive ELISA and at the
mRNA level  by Northern  blot  analysis. In  unstimu-
lated cultures no or very low levels of GM-CSF mRNA
were detected. After incubation with IL-1 (100U/ml)
or TNF-a (500U/ml) for 6h, significant GM-CSF-mRNA
expression was induced. IL-1 was shown to have a
stronger stimulatory effect than TNF-a (Figs 1 and 2B).
These RNA-data were confirmed at the protein level.
IL-1 and TNF-a incubation for 24-h induced GM-CSF
secretion into stromal cell culture supernatants with
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FIG. 1. Induction of GM-CSF mRNA in human bone marrow
stromal  cells.  Confluent  secondary  stromal  cultures  were
incubated for 6h in medium alone or with the addition of IL-1
(100U/ml), TNF-a (500U/ml), IL-1 plus TNF-a with or without
8BrcAMP  (0.5mM).  Total  cellular  RNA  was  prepared  and
subjected  to  Northern-blot  analysis  with  cDNA  probe  for
human  GM-CSF.  The  18  and  28S  rRNA  from  ethidium
bromide stained gel is shown as loading control. Data are
representative for two experiments with stromal cells from
different donors.IL-1 again being the stronger stimulus.  Because the
absolute  amount  of  GM-CSF  expression  varied
between  experiments,  the  protein  level  in  culture
supernatants from pooled experiments is depicted in
Fig. 2A relative to the maximal stimulation.
The  addition  of  the  cAMP  agonist  8BrcAMP  to
stromal cell cultures, stimulated by IL-1, TNF-a or the
combination  of  IL-1  and  TNF-a ,  resulted  in  sig-
nificantly  reduced  GM-CSF  mRNA  expression.  Sim-
ilarly, the GM-CSF protein secretion, induced by IL-1
or  TNF-a ,  was  inhibited  with  8BrcAMP  (0.5mM)
coincubation  by  65.5  ±  2.9%  or  61.6  ±  6.1% ,
respectively. These results were obtained by pooling
data from three independent experiments (Figs 1 and
2).  Dose  dependence  of  the  modulatory  effect  of
8BrcAMP  on  GM-CSF  secretion  was  evaluated  at
concentrations between 0.1 and 1.0mM. Significant
inhibition of  IL-1  stimulated GM-CSF  secretion was
observed  at  8BrcAMP  concentrations  of  0.1  to
0.25mM  and  the  maximal  inhibition  was  seen  at
concentrations between 0.75 and 1mM (Fig. 3).
Different cAMP agonists inhibit GM-CSF
expression in stimulated human bone marrow
stromal cells
In order to evaluate whether the results obtained by
8BrcAMP incubation of human bone marrow stromal
cells on GM-CSF expression could be generalized to
other cAMP agonists we tested a panel of substances.
IL-1 stimulated GM-CSF protein secretion into stromal
cell  supernatants  was  inhibited  by  all  investigated
cAMP agonists including forskolin at 10m M (81.6 ±
5.8 inhibition), dibutyryl-cAMP at 1mM (66.1 ± 8.1%
inhibition), pertussis toxin at 1m g/ml (59.0 ± 4.6%
inhibition), and PGE2 1m g/ml (36.4 ± 14%  inhibition).
These data were confirmed by Northern blot analysis
at the mRNA level. The coincubation of stromal cell
cultures  stimulated  by  IL-1  with  forskolin,  PGE2,
dibutyryl-cAMP ,  and  pertussis  toxin  led  to  abolish-
ment  of  GM-CSF  mRNA  expression.  On  the  other
hand,  the  cyclooxygenase  inhibitor  and  indirect
cAMP  antagonist  indomethacin  had  no  significant
GM-CSF expression in human bone marrow stromal cells
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FIG. 2. Effect of 8BrcAMP on the expression of GM-CSF by
human stromal cells. Confluent secondary stromal cultures
were incubated in medium alone or with the addition of IL-1
(100U/ml), TNF-a (500U/ml), 8BrcAMP (0.5mM) or combina-
tions  as  indicated.  (A)  After  incubation  for  24h,  GM-CSF
concentrations in the supernatants were assessed using a
specific ELISA. GM-CSF levels are presented as  deviation
from maximal stimulation. Single experiments were carried
out in triplicate, and data from three independent experi-
ments are summarized as mean ± SEM. (B). After incubation
for 6h, total cellular RNA was prepared and subjected to
Northern-blot analysis with cDNA probe for human GM-CSF.
The 18 and 28S rRNA from ethidium bromide stained gel is
shown as loading control. Data are representative for three
experiments with stromal cells from different donors.
(a)
(b)
FIG. 3. Dose-dependents of the inhibitory effect of 8BrcAMP
on  the  synthesis  of  GM-CSF  in  stromal  cells.  Confluent
secondary  stromal  cultures  were  incubated  for  24h  in
medium containing IL-1 (100U/ml) with increasing concen-
trations of 8BrCAMP ranging from 0.1 to 1mM. The GM-CSF
concentration  in  the  supernatants  was  assessed  using  a
specific ELISA. Experiments were carried out in triplicate,
and data from three independent experiments are summa-
rized as mean ± SEM.inhibitory  influence  on  GM-CSF  protein  or  mRNA
expression (Fig. 4).
Discussion
The presented data show that GM-CSF is produced in
adherent human bone marrow stromal cell cultures
after  stimulation  with  inflammatory  cytokines  IL-1
and TNF-a . This effect has previously been reported
by  several  other  groups.9–11 Some  authors  also
described the endogenous expression of GM-CSF in
the  adherent  layer  of  human  Dexter-type  cultures
without external cytokine stimulation. GM-CSF mRNA
could until now unequivocally only be demonstrated
by  PCR  technique  in  stromal  cells  cultures.9,10,12
Charbord et al.13 showed the inhibition of GM-CSF
activity in complete Dexter-type cultures by neutral-
izing monoclonal antibodies that suppressed 70% of
the endogenous CFU-GM. In our culture system, we
could not demonstrate significant production of GM-
CSF  in  human  stromal  cell  cultures  by  a  sensitive
ELISA. This fact could be due to the deprivation of
haematopoietic cells. These cells are likely to exert a
paracrine stimulatory  effect on adherent mesenchy-
mal stromal cells and explain the constitutive expres-
sion of GM-CSF in complete Dexter-type cultures.
Both IL-1 and TNF-a were able to induce GM-CSF in
bone marrow stromal cell cultures, with IL-1 being
the more potent inducer. These results are in accord-
ance with published data.11
In  a  variety  of  investigated systems,  it  has  been
shown that incubation with cAMP agonists causes a
differential  effect  on  the  production  of  cytokines.
While  some  cytokines,  such  as  interleukin-6  and
leukaemia inhibitory factor, are induced by increased
intracellular cAMP concentrations, the expression of
other cytokines is inhibited.14–16 To the latter group
belong  macrophage-colony  stimulating  factor,  IL-1,
platelet derived growth factor, and GM-CSF .17–19 Patil
and Borch reported on the inhibitory role of PGE2 on
GM-CSF production in human fibroblasts. This effect
was mediated by increased intracellular cAMP levels.
Our group has described a similar finding of PGE2 and
other cAMP agonists inhibiting GM-CSF expression in
a  murine  bone  marrow  stromal  cell  line.20,21 The
present  data  proves  the  same  inhibitory  effect  of
increased intracellular cAMP concentration in human
bone marrow stromal cells at the protein and mRNA
level. This inhibition was dose-dependent as shown
by  increasing  suppression  of  IL-1-induced  GM-CSF
protein production by the water-soluble cAMP ana-
logue 8BrcAMP . Maximal inhibition of about 60% was
obtained at a concentration of 0.75mM. The inhibi-
tory action of 8BrcAMP was demonstrated on GM-CSF
expression induced by IL-1, TNF-a , or the combina-
tion  of  IL-1  and TNF-a . The  interference  with  the
stimulatory action of different cytokines indicates that
cAMP  interacts  with  components  that  are  either
shared  among  different  signalling  pathways  or  act
downstream  from  the  convergence  point  of  these
pathways.  However  in  earlier  experiments  on  the
murine bone marrow stromal cell line +/+-1.LDA11
we demonstrated that IL-1 and TNF-a incubation had
no influence on intracellular cAMP levels.20
In addition to the water soluble cAMP analogues
8BrcAMP  and  dibutyryl-cAMP  other  cAMP  agonists
G. Bug et al.
198 Mediators of Inflammation · Vol 7 · 1998
FIG. 4. Effect of different cAMP antagonists on the expression
of GM-CSF by  human  stromal  cells. Confluent  secondary
stromal cultures were incubated in medium alone or with the
addition of the indicated stimuli. Concentrations used: IL-1
(100U/ml), forskolin (10m M), PGE2 (1m M), dibuturyl-cAMP
(1mM), pertussis toxin (1m g/ml), indomethacin (10m M). (A)
After  incubation  for  24h,  GM-CSF  concentrations  in  the
supernatants were assessed using a specific ELISA. GM-CSF
levels are presented as deviation from maximal stimulation.
Single experiments were carried out in triplicate, and data
from  three  independent  experiments  are  summarized  as
mean ± SEM. (B) After incubation for 6h total cellular RNA
was prepared and subjected to Northern-blot analysis with
cDNA probe for human GM-CSF. The 18 and 28S rRNA from
ethidium bromide stained gel is shown as loading control.
Data are representative for two experiments with stromal
cells from different donors.
(a)
(b)like forskolin, PGE2 or pertussis toxin were shown to
inhibit GM-CSF expression. PGE2 is known to increase
the  intracellular  cAMP  synthesis  in  mesenchymal
bone marrow cells.22 In contrast to data obtained by
Hamilton et al.23 in synovial fibroblasts our data did
not  show  an  additive  effect  of  the  cyclooxygenase
inhibitor indomethacin on the IL-1 stimulated GM-CSF
induction. This discrepancy may be related to differ-
ent  levels  of  cyclooxygenase  activity  in  different
cellular systems. A regulatory loop has been described
by which IL-1 induced GM-CSF expression is down-
regulated later by IL-1 induced PGE2.24 Prostaglandins
are known to exert an inhibitory action on prolifera-
tion  of  haematopoietic  progenitor  cells.25–27 The
mechanism  of  this  effect  is  not  completely  under-
stood yet. It seems likely that this inhibition, at least in
part,  is  mediated  by  a  decreased  expression  of
haematopoietic growth factors like GM-CSF by acces-
sory cells.
The mechanism of action by which cAMP decrea-
ses  GM-CSF  expression  in  stromal  cells  has  been
evaluated  by our  group  in a  murine  bone  marrow
stromal  cell  line  before.  Cyclic-AMP  was  found  to
induce  the  synthesis  of  a  protein  which  in  turn
decreased GM-CSF-mRNA stability.21The same mecha-
nism  of  action  has  been  reported  in  human  lung
fibroblasts.
24 Overall  the  present  data  provide  evi-
dence for the previously described inhibitory effect of
the second messenger cAMP on the GM-CSF expres-
sion occurring in human bone marrow stromal cells.
This signalling pathway may be involved in the action
of  different  inhibitory  hormones  like  PGE2 on
haematopoiesis.
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